Sponsors

19th Annual South Beach Symposium presented by LiVDerm

February 5-7, 2021

Online

ACTIVITY OVERVIEW

At The Medical Dermatology Summit, led by renowned clinical authorities, attendees will gain actionable knowledge on the most relevant topics in medical dermatology including the impact of COVID-19 on the dermatology industry, cutaneous oncology, hair restoration, and much more all from the safety of their home. The summit will deliver an interactive educational experience that optimizes all the advantages of virtual education with live-streamed sessions, on-demand content, faculty Q&A, live engagement, and networking with key industry opinion leaders.

TARGET AUDIENCE

This symposium is designed for an audience of physicians, nurses and professional staff members of medical practices specializing in dermatology, pediatric dermatology, plastic surgery, cosmetic surgery and other dermatologic medical procedures.

LEARNING OBJECTIVES

Upon completion of the educational activity, participants should be able to: • Summarize new and emerging therapies for the treatment of acne. • Evaluate the efficacy and safety of acne treatments, including the need to appropriately modify therapy and practice antibiotic stewardship. • Describe recent advances in the treatment of actinic keratosis that have high levels of patient satisfaction, decreased treatment duration, and fewer side-effects. • List the pathogenic mechanisms of atopic dermatitis. • Review individualized treatment plans for patients with moderate-to-severe atopic dermatitis based on current guideline recommendations, the safety and efficacy of new and emerging treatment options, comorbidities, and patients’ quality of life. • List current and emerging treatment options for alopecia areata. • Review and compare efficacy and safety of biologic agents, devices, and techniques currently available in hair restoration for androgenic alopecia. • Define the efficacy and safety of emerging treatment options for hidradenitis suppurativa. • Review the new and emerging treatment options for hyperhidrosis. • Summarize new and emerging therapies for the treatment of psoriasis. • Review the significance of addressing comorbidities as important components of psoriasis therapy. • Review the clinical presentation of rosacea in order to ensure timely diagnosis. • Summarize traditional, new and emerging therapies for the treatment of rosacea. • Define the efficacy and safety of the current and new treatment options for seborrheic keratosis. • Interpret latest clinical evidence for emerging treatments of keloids.

CRITERIA FOR SUCCESS

Statements of credit will be awarded based on the participant’s attendance and submission of the activity evaluation form. A statement of credit will be available upon completion of an online evaluation/claimed credit form at www.southbeachsymposium.org. You must participate in the entire activity to receive credit. If you have questions about this CE activity, please contact AKH Inc. at tbrignoni@akhcme.com.

Credit provided by AKH Inc., Advancing Knowledge in Healthcare

In support of improving patient care, this activity has been planned and implemented by AKH Inc., Advancing Knowledge in Healthcare and Tarsus Cardio dba LiVDerm. AKH Inc., Advancing Knowledge in Healthcare is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

This activity was planned by and for the healthcare team, and learners will receive 16.5 Interprofessional Continuing Education (IPCE) credit for learning and change.

Physician

AKH Inc., Advancing Knowledge in Healthcare designates this live activity for a maximum of 16.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurse

16.5 ANCC contact hours

Physician Assistant

AKH Inc., Advancing Knowledge in Healthcare has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 16.5 AAPA Category 1 CME credits. PAs should only claim credit commensurate with the extent of their participation.

COMMERCIAL SUPPORT

This activity is supported by educational grants from Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC, Pfizer Inc., Sirnaomics, Inc.

DISCLOSURE

It is the policy of AKH Inc. to ensure independence, balance, objectivity, scientific rigor, and integrity in all of its continuing education activities. The author must disclose to the participants any significant relationships with ineligible companies whose products or devices may be mentioned in the activity or with the commercial supporter of this continuing education activity. Identified conflicts of interest are mitigated by AKH prior to accreditation of the activity. AKH planners and reviewers have no relevant financial relationships to disclose.

DISCLOSURES NAME

RELATIONSHIP Glynis Ablon, MD, FAAD N/A Marc Avram, MD N/A

Brian Berman, MD, PhD

Diane Berson, MD Consultant

Neal Bhatia, MD

Consultant Markus Boos, MD PhD N/A Valerie Callender, MD Consultant Speakers Bureau Clay Cockerell, MD Consultant David Cohen, MD, MPH Board of Directors Consultant

FIDE. (FIDE receives industry sponsorship from AbbVie, Almirall, Amgen, Bausch and Lomb, Bristol-Myers Squibb, Celgene Dermavant, Dermira, Janssen, Kyowa Hakko Kirin, LEO, Lilly, Novartis, Ortho Dermatologics, Pfizer, Sanofi Genzyme, Sun Pharma, UCB, Valeant) James Del Rosso, DO Consultant

Seemal Desai, MD Contracted Research

Speakers Bureau

Advisory Board Consultant

Contracted Research

Speakers Bureau Stock Brian Ginsberg, MD N/A Michael Gold, MD Consultant COMPANY Nothing to disclose Nothing to disclose Biofrontera, Ferndale Laboratories, Inc., Galderma Laboratories, L.P., GlaxoSmithKline, LEO Pharma - Advisory Board, Medimetriks Pharmaceuticals Inc., Miragen - Consultant Honoraria, Encore - Consultant, Siranomics - Consultant, Pierre-Fabre - Consultant, Pfizer - Consultant, Lemonex - Consultant, Novan - Consultant Honoraria, Novartis Pharmaceuticals Corp. - Advisory Board & Speaker Honoraria, Sonoma (Oculus Innovative Sciences, Inc.) - Consultant Stock Options, Sensus - Speaker Consultant Honoraria Investigator, Smith & Nephew - Advisory Board Honoraria, TopMD - Advisory Board, Ortho Dermatologics/Valeant - Advisory Board, Cutanea - Advisory Board, Birch BioMed - Advisory Board, Encore Dermatology - Consultant, Aclaris - Consultant, Aiviva - Consultant, Clark Pharmaceutical, Tigercat Pharma, Inc, Menlo Therapeutics - Consultant, BMS - Consultant, Pulse - Consultant, Almirall - Consultant, Mediwound - Consultant Aclaris, Allergan, Almirall, Cassiopea, CLN, Crown, Evolus, Ferndale, L'Oreal, Ortho Derm, Procter and Gamble, Regimen Pro, Revance, Sonoma Almirall, Biofrontera, Ortho, Sun Pharma Nothing to disclose Aerolase Ortho Dermatologics Almirall Kadmon, Timber, Evommune, Dermira Asana, Dermavant, Celgene, Cutanea, Ferndale Laboratories, Ferrer, FSJ, Leo, Medimetriks, UCB

Almirall, Bausch (Ortho), BioPharmX, Cassiopea, Inc., EPI Health, Galderma, LeoPharma, Mayne Pharma, Novan, SolGel, Sonoma, Sun Pharma, Vyne Therapeutics Inc Almirall, Bausch (Ortho), BioPharmx, Galderma, LeoPharma, Mayne Pharma, Novan, SolGel, Sun Pharma, Vyne Therapeutics Inc Almirall, Bausch (Ortho), EPI Health, Galderma, LeoPharma, Mayne Pharma, Sun Pharma, Vyne Therapeutics Inc Dermavan Sciences, Foundation for Research & Education of Dermatology Galderma Laboratories, Cassiopea SpA, Ortho Dermatologics, SkinCeuticals LLC, Dermira, Almirall, Scientis Sente Labs, Foamix, Pfizer Inc., Verrica Pharmaceuticals, Inc, Ferndale, Avita, Gore Range Capital, Incyte Corporation, Bristol Myers Squibb, UCB Abbvie, Atacama, Incyte Corporation, Dermavant Sciences, Novan, AOBiome, LLC, Brickell Biotec Almirall, Ortho Dermatologics Gore Range Capital Nothing to disclose Aerolase, Alastin, Allergan, Alma Lasers, Almirall, BioFrontera, Clarify MD, Croma, DefenAge, Dermira, EndyMed, Essence Novel, Galderma, Hugel, IntraDerm, Invasix / InMode, Johnson & Johnson, Joylux, Lumenis, Merz, MTF, NanoPass, Neauvia, Novartis, Pierre Fabre / Glytone, Revision, Sensus, Senté, Skinbetter Science, Sofregen, Stratpharma, Suneva, Candela, Viviscal, Zimmer

David Goldberg, MD N/A Dee Anna Glaser, MD Consultant Contracted Research Speakers Bureau Brad Glick, DO, MPH, FAAD N/A Alice Gottlieb, MD, PhD Consultant Contracted Research Stock Options Andrew Heyman, MD N/A Rajani Katta, MD Royalty Mark Kaufmann, MD Stock Options Jonette Keri, MD, PhD Speakers Bureau Leon Kircik, MD Advisory Board

Consultant

Contracted Research

Speakers Bureau

Stock Robert Kirsner, MD, PhD N/A Mark Lebwohl, MD Consultant

Peter Lio, MD Contracted Research

Consultant

Contracted Research Royalties Speakers Bureau Stock Options Nothing to disclose Brickell, Candesant, Dermira, Revance, Recross Allergan, Atacama, Brickell, Dermira, Galderma Allergan, Dermira, Galderma Nothing to disclose Janssen , Novartis , UCB Janssen , Novartis and UCB (paid to MT Sinai School of Medicine) XBiotech Nothing to disclose Author of a book for the general public on diet and dermatology Modernizing Medicine, Klara Foamix Pharmcueticals Aclaris, Allergan, Inc., Almirall, Anacor Pharmaceuticals, Biogen-Idec, Cassiopea, Inc., Colbar, Celgene, Cipher, Connetics Corporation, EOS, Exeltis, Ferndale, Laboratories, Inc., Foamix, Genentech, Inc., Intendis, Innocutis, Isdin, Johnson & Johnson, Nano Bio, OrthoNeutogena, Promius, Quinnova, SkinMedica, Inc., Stiefel Laboratories, Inc., Sun Pharma, Valeant Pharmaceuticals Intl, Warner-Chilcott Allergan, Inc., Almirall, Amgen, Inc., Anacor Pharmaceuticals, Cassiopea, Inc., Colbar, Cipher, CollaGenex, Connetics Corporation, Exeltis, Foamix, Genentech, Inc., Intendis, Isdin, Johnson & Johnson, Laboratory Skin Care Inc, LEO, Medical International Technologies, Merck, Merz, Novartis AG, OrthoNeutrogena, Promius, PuraCap, SkinMedica, Inc., Stiefel Laboratories, Inc., Sun Pharma, Taro, UCB, Valeant Pharmaceuticals, ZAGE Acambis, Allergan, Inc., Amgen, Inc., Anacor Pharmaceuticals, Astellas Pharma US, Inc., Asubio, Berlex Laboratories (Bayer HealthCare Pharmaceuticals),Biolife, Biopelle, Boehringer-Ingleheim, Breckinridge Pharma, Celgene, Centocor, Inc. Cellceutix, Coherus, CollaGenex, Combinatrix, Connetics Corporation, Coria, Dermavant, Dermira, Dow Pharmaceutical Sciences, Inc., DUSA, Eli Lilly, Exeltis, Ferndale Laboratories, Inc., Foamix, Genentech, Inc., GlaxoSmithKline, PLC, Healthpoint, LTD, Idera, Intendis, Johnson & Johnson, LEO, L’Oreal, 3M, Maruho, Medicis Pharmaceutical Corp., Merck, Nano Bio, Novartis AG, Noven Pharmaceuticals, Nucryst Pharmaceuticals Corp, Obagi, Onset, OrthoNeutrogena, Promius, QLT, Inc. Quinnova, Quatrix, , PharmaDerm, Pfizer, SkinMedica, Inc., Stiefal Laboratories, Inc., Sun Pharma, TolerRX, UCB, Valeant Pharmaceuticals Intl, Warner-Chilcott, XenoPort Abbott Laboratories, Allergan, Inc., Amgen, Inc., Assos Pharma, Astellas Pharma US, Inc., Cipher, CollaGenex, Connectics Corporation, Dermik Laboratories, Embil Pharmaceuticals, Exeltis, Foamix, Genentech, Inc., Innocutix, Innoval, Johnson & Johnson, LEO, L’Oreal, 3M, Onset, OrthoNeutrogena, PediaPharma, PharmaDerm, Serono (Merck Serono International SA),SkinMedica, Inc., Stiefel Laboratories, Inc., Sun Pharma, Taro, Triax, UCB, Valeant Pharmaceuticals, Intl, Warner-Chilcott, Johnson & Johnson Nothing to disclose Aditum Bio, Allergan, Almirall, Arcutis, Inc., Avotres Therapeutics, BirchBioMed Inc., BMD skincare, Boehringer-Ingelheim, Bristol-Myers Squibb, Cara Therapeutics, Castle Biosciences, Corrona, Dermavant Sciences, Evelo, Evommune, Facilitate International Dermatologic Education, Foundation for Research and Education in Dermatology, Inozyme Pharma, Kyowa Kirin, LEO Pharma, Meiji Seika Pharma, Menlo, Mitsubishi, Neuroderm, Pfizer, Promius/Dr. Reddy's Laboratories, Serono, Theravance, and Verrica Abbvie, Amgen, Arcutis, Boehringer Ingelheim, Dermavant, Eli Lilly, Evommune, Incyte, Janssen Research & Development, LLC, Leo Pharmaceutucals, Ortho Dermatologics, Pfizer, and UCB, Inc UCB, Dermavant, Regeneron/Sanofi Genzyme, Dermira, Pfizer, LEO Pharmaceuticals, AbbVie, Kiniksa, Eli Lilly, Micreos, L'Oreal, Pierre-Fabre, Johnson & Johnson, Level Ex, Unilever, Menlo Therapeutics, Theraplex, IntraDerm, Exeltis, AOBiome, Realm Therapeutics, Altus Labs, Galderma, Verrica, Arbonne, Amyris, Bodewell, Burt's Bees, Kimberly-Clark National Eczema Association, AOBiome, Regeneron/Sanofi Genzyme, and AbbVie Theraplex: Theraplex AIM OTC moisturizer Regeneron/Sanofi Genzyme, Pfizer, Eli Lilly, Galderma, L'Oreal Micreos Altus Labs

Z. Paul Lorenc, MD, FACS N/A Jose Lutzky, MD N/A Andrea Maderal, MD N/A Amy McMichael, MD Consultant

Contracted Research

Royalties Mark Nestor, MD, PhD N/A Darrell Rigel, MD Consultant

Contracted Research Grants/Research Theodore Rosen, MD N/A Anthony Rossi, MD Equipment Donated William Roth, MD Consultant/advisory board Contracted Research Emily Ruiz, MD MPH Consultant Contracted Research Linda Stein Gold, MD Consultant

Contracted Research

Speakers Bureau Nothing to disclose Nothing to disclose Nothing to disclose Allergan, Almirall, Bioniz, Cassiopea, Covance, eResearch Technology, Inc., Galderma, Incyte, Johnson & Johnson, Keranetics, Lilly, Merck & Co., Inc., Pfizer Proctor & Gamble, Revian, Samumed Allergan, Cassiopea, Concert Pharmaceuticals, Incyte, Pfizer Proctor & Gamble, Samumed Informa Healthcare, UpToDate Nothing to disclose Beiersdorf, Inc., Advisory Board Honoraria, Derm Tech International Advisory Board Honoraria, Castle Biosciences Advisory Board Honoraria, Ferndale Laboratories, Inc. Consultant Honoraria, Derm Tech International Consultant Honoraria, SciBASE Consultant Honoraria Castle Biosciences Investigator Stock Foamix Nothing to disclose Caliber ID Sensus Healthcare (no compensation) Sensus Healthcare Genentech, Regeneron/Sanofi Merck, Regeneron Galderma, Sun, Pfizer, Amgen, Sanofi, Regeneron, Vyne Therapeutics Inc, Almirall, BMS, UCB, Sol Gel, Ortho Derm Galderma, Sun, Pfizer, Amgen, Sanofi, Regeneron, Vyne Therapeutics Inc, Almirall, UCB, Sol Gel, Ortho Derm, Novartis, AbbVie Galderma, Sun, Pfizer, Amgen, Sanofi, Regeneron, Vyne Therapeutics Inc, Ortho Derm

Sahar Swidan, PharmD Employer Speakers Bureau Antonella Tosti, MD Consultant

Jill Waibel, MD

N/A Susan Weinkle, MD Consultant

Contracted Research Speakers Bureau Stock Options Gil Yosipovitch, MD N/A Dorothy Caputo, MA, BSN, RN - CE Director of Accreditations N/A

LiVDerm Planners and Reviewers N/A Pharmacy Solutions (President & CEO) Amgen, Biohaven Almirall, Bristol Myers Squibb, DS Laboratories, Leo Pharmaceuticals, Lilly, Monat Global, P&G, Thirty Madison Nothing to disclose Allergan, Ethicon, Galderma, Merz Aesthetics, Proctor and Gamble, Teoxane, Evolus, Sinclair, Revance, Almirall Allergan, Derm Avance, Galderma, Teoxane, Evolus, Sinclair, Revance Allergan, Ethicon, Galderma, Merz Aesthetics Derm Avance Nothing to disclose Nothing to disclose

Nothing to disclose

AKH Planners and Reviewers N/A Nothing to disclose All of the relevant financial relationships listed for these individuals have been mitigated.

DISCLAIMER

This course is designed solely to provide the healthcare professional with information to assist in his/her practice and professional development and is not to be considered a diagnostic tool to replace professional advice or treatment. The course serves as a general guide to the healthcare professional, and therefore, cannot be considered as giving legal, nursing, medical, or other professional advice in specific cases. AKH Inc. specifically disclaim responsibility for any adverse consequences resulting directly or indirectly from information in the course, for undetected error, or through participant’s misunderstanding of the content.

DISCLOSURE OF UNLABELED USE AND INVESTIGATIONAL PRODUCT

This educational activity may include discussion of uses of agents that are investigational and/or unapproved by the FDA. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Clinical Update: Novel Agents for the Long-Term Management of Moderate-to-Severe Atopic Dermatitis

February 6, 2021

Online

ACTIVITY OVERVIEW

The increasing incidence of Atopic dermatitis (AD) and poor recognition of the disease in some patient groups is a public health concern. AD symptoms and its daily management cause significant effects on quality of life for both patients and caregivers. AD is associated with an increase in other atopic manifestations as well as with serious comorbidities that can greatly affect overall patient health and wellbeing (Silverberg 2015; Simpson 2012; Yu 2016; Zheng 2011). Timely and adequate treatment of AD is essential for helping to promote better long-term outcomes and quality of life and may help prevent the development of other atopic conditions (Leung 2014). However, the treatment of AD is a clinical challenge. Patients continue to report treatment dissatisfaction, recurrent flares, and impaired quality of life (Silverberg 2018; Wei 2019). Targeted immunomodulatory agents, based on recent advances in the understanding of AD pathophysiology, represent additional options for longterm control, with one agent that is FDA approved and several others in advanced clinical development (Kalamaha 2019). Thus, additional education about current and emerging long-term strategies to AD management is crucial for their interpretation and application to clinical practice.

TARGET AUDIENCE

This symposium is designed for an audience of physicians, nurses and professional staff members of medical practices specializing in dermatology as well as allergists, primary care physician, nurses, nurse practitioners, physician assistants and pharmacists.

LEARNING OBJECTIVES

Upon completion of the educational activity, participants should be able to: • Interpret the efficacy and safety of current non-pharmacological and pharmacological treatments for AD and their limitations in long-term disease management. • Summarize the mechanisms of action and evidence with new and emerging targeted immunomodulatory agents for long-term AD management • Develop individualized treatment plans for patients with moderate-to-severe AD that go beyond just treating flares and symptoms in order to optimize long-term control and overall quality of life

CRITERIA FOR SUCCESS

Statements of credit will be awarded based on the participant’s attendance and submission of the activity evaluation form. A statement of credit will be available upon completion of an online evaluation/claimed credit form at www.southbeachsymposium.org. You must participate in the entire activity to receive credit. If you have questions about this CE activity, please contact AKH Inc. at tbrignoni@akhcme.com.

Credit provided by AKH Inc., Advancing Knowledge in Healthcare

In support of improving patient care, this activity has been planned and implemented by AKH Inc., Advancing Knowledge in Healthcare and Tarsus Cardio dba LiVDerm. AKH Inc., Advancing Knowledge in Healthcare is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

This activity was planned by and for the healthcare team, and learners will receive 1 Interprofessional Continuing Education (IPCE) credit for learning and change.

Physician

AKH Inc., Advancing Knowledge in Healthcare designates this live activity for a maximum of 1 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurse

1 ANCC contact hours

Physician Assistant

AKH Inc., Advancing Knowledge in Healthcare has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1 AAPA Category 1 CME credits. PAs should only claim credit commensurate with the extent of their participation.

Commercial Support

This activity is supported by educational grants from Incyte Corporation, Pfizer Inc.

DISCLOSURE

It is the policy of AKH Inc. to ensure independence, balance, objectivity, scientific rigor, and integrity in all of its continuing education activities. The author must disclose to the participants any significant relationships with ineligible companies whose products or devices may be mentioned in the activity or with the commercial supporter of this continuing education activity. Identified conflicts of interest are mitigated by AKH prior to accreditation of the activity. AKH planners and reviewers have no relevant financial relationships to disclose.

DISCLOSURE

It is the policy of AKH Inc. to ensure independence, balance, objectivity, scientific rigor, and integrity in all of its continuing education activities. The author must disclose to the participants any significant relationships with ineligible companies whose products or devices may be mentioned in the activity or with the commercial supporter of this continuing education activity. Identified conflicts of interest are mitigated by AKH prior to accreditation of the activity. AKH planners and reviewers have no relevant

DISCLAIMER

This course is designed solely to provide the healthcare professional with information to assist in his/her practice and professional development and is not to be considered a diagnostic tool to replace professional advice or treatment. The course serves as a general guide to the healthcare professional, and therefore, cannot be considered as giving legal, nursing, medical, or other professional advice in specific cases. AKH Inc. specifically disclaim responsibility for any adverse consequences resulting directly or indirectly from information in the course, for undetected error, or through participant’s misunderstanding of the content.

DISCLOSURE OF UNLABELED USE AND INVESTIGATIONAL PRODUCT

This educational activity may include discussion of uses of agents that are investigational and/or unapproved by the FDA. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

DISCLOSURES

NAME RELATIONSHIP COMPANY

Andrew Alexis, MD Consultant Leo, Novartis, Menlo, Galderma, Pfizer, Sanofi-Regeneron, Dermavant, Unilever, Beiersdorf, Valeant, L’Oreal, BMS, Menlo, Scientis, Bausch health , UCB, Foamix , Cassiopea, Arcutis, Janssen, Allergan, Almirall, Abbvie, Sol-Gel (Self); Pfizer, Sanofi-Regeneron (Spouse/partner) Contracted Research Leo, Novartis, Almirall, Bristol-Myers-Squibb, Celgene, Menlo, Galderma, Valeant (Bausch Health), Cara, Arcutis

Peter Lio, MD Consultant UCB, Dermavant, Regeneron/Sanofi Genzyme, Dermira, Pfizer, LEO Pharmaceuticals, AbbVie, Kiniksa, Eli Lilly, Micreos, L'Oreal, Pierre-Fabre, Johnson & Johnson, Level Ex, Unilever, Menlo Therapeutics, Theraplex, IntraDerm, Exeltis, AOBiome, Realm Therapeutics, Altus Labs, Galderma, Verrica, Arbonne, Amyris, Bodewell, Burt's Bees, Kimberly-Clark Contracted Research National Eczema Association, AOBiome, Regeneron/Sanofi Genzyme, and AbbVie

Royalties Theraplex: Theraplex AIM OTC moisturizer

Speakers Bureau Regeneron/Sanofi Genzyme, Pfizer, Eli Lilly, Galderma, L'Oreal

Stock Options Micreos Altus Labs

Linda Stein Gold, MD Consultant Galderma, Sun, Pfizer, Amgen, Sanofi, Regeneron, Vyne Therapeutics Inc, Almirall, BMS, UCB, Sol Gel, Ortho Derm

Contracted Research Galderma, Sun, Pfizer, Amgen, Sanofi, Regeneron, Vyne Therapeutics Inc, Almirall, UCB, Sol Gel, Ortho Derm, Novartis, AbbVie

Speakers Bureau Galderma, Sun, Pfizer, Amgen, Sanofi, Regeneron, Vyne Therapeutics Inc, Ortho Derm

Dorothy Caputo, MA, BSN, RN - CE Director of Accreditations LiVDerm Planners and Reviewers N/A

N/A Nothing to disclose

Nothing to disclose

AKH Planners and Reviewers N/A Nothing to disclose

All of the relevant financial relationships listed for these individuals have been mitigated.

Time to Think About Both Skin and Joint Disease: Optimizing the Diagnosis and Management of Psoriatic Arthritis Through Multidisciplinary, Patient-Centered Care

February 6, 2021

Online

ACTIVITY OVERVIEW

Psoriasis is a chronic and inflammatory skin disease with potential systemic implications that affects 7.5 million people in the United States (Bhushan 2016; Soleymani 2018) that can lead to several comorbidities, including psoriatic arthritis, obesity, metabolic syndrome, and cardiovascular disease (Soleymani 2018). Early diagnosis and treatment are crucial in managing PsA, and clinicians need to understand the impact of both skin and joint aspects of psoriasis and PsA in order to minimize impact on patients’ quality of life (QOL). Current methods to assess disease severity may not be practical to use in routine care, contributing to the undertreatment or incorrect treatment of PsA (Elmets 2019). Due to ongoing suboptimal management of PsA, there is a need to educate clinicians that treat patients with PsA on the diagnosis and current treatment approach, particularly in light of new guidelines for psoriasis (Elmets 2019) and PsA (Singh 2019).

TARGET AUDIENCE

This symposium is designed for an audience of physicians, nurses and professional staff members of medical practices specializing in dermatology, plastic surgery, cosmetic surgery, rheumatology and other dermatologic medical procedures.

LEARNING OBJECTIVES

Upon completion of the educational activity, participants should be able to: • Identify key clinical features of PsA in order to improve timely screening, diagnosis, or referral • Utilize practical strategies to evaluate PsA severity that incorporate both joint and skin manifestation in order to guide treatment • Develop individualized treatment strategies for patients with PsA based on the efficacy and safety of current and emerging pharmacotherapies, evidence-based guidelines, and patient specific needs and preferences

CRITERIA FOR SUCCESS

Statements of credit will be awarded based on the participant’s attendance and submission of the activity evaluation form. A statement of credit will be available upon completion of an online evaluation/claimed credit form at www.southbeachsymposium.org. You must participate in the entire activity to receive credit. If you have questions about this CE activity, please contact AKH Inc. at tbrignoni@akhcme.com.

Credit provided by AKH Inc., Advancing Knowledge in Healthcare

In support of improving patient care, this activity has been planned and implemented by AKH Inc., Advancing Knowledge in Healthcare and Tarsus Cardio dba LiVDerm. AKH Inc., Advancing Knowledge in Healthcare is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

This activity was planned by and for the healthcare team, and learners will receive 1.25 Interprofessional Continuing Education (IPCE) credit for learning and change.

Physician

AKH Inc., Advancing Knowledge in Healthcare designates this live activity for a maximum of 1.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurse

1.25 ANCC contact hours

Physician Assistant

AKH Inc., Advancing Knowledge in Healthcare has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.25 AAPA Category 1 CME credits. PAs should only claim credit commensurate with the extent of their participation.

COMMERCIAL SUPPORT

This activity is supported by educational grants from Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC.

DISCLOSURE

It is the policy of AKH Inc. to ensure independence, balance, objectivity, scientific rigor, and integrity in all of its continuing education activities. The author must disclose to the participants any significant relationships with ineligible companies whose products or devices may be mentioned in the activity or with the commercial supporter of this continuing education activity. Identified conflicts of interest are mitigated by AKH prior to accreditation of the activity. AKH planners and reviewers have no relevant financial relationships to disclose.

DISCLAIMER

This course is designed solely to provide the healthcare professional with information to assist in his/her practice and professional development and is not to be considered a diagnostic tool to replace professional advice or treatment. The course serves as a general guide to the healthcare professional, and therefore, cannot be considered as giving legal, nursing, medical, or other professional advice in specific cases. AKH Inc. specifically disclaim responsibility for any adverse consequences resulting directly or indirectly from information in the course, for undetected error, or through participant’s misunderstanding of the content.

DISCLOSURE OF UNLABELED USE AND INVESTIGATIONAL PRODUCT

This educational activity may include discussion of uses of agents that are investigational and/or unapproved by the FDA. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclosures

NAME RELATIONSHIP COMPANY

Alice Gottlieb, MD, PhD Consultant Janssen , Novartis , UCB

Joseph Merola, MD, MMSc

Alexis Ogdie-Beatty, MD Contracted Research

Stock Options Janssen , Novartis and UCB (paid to MT Sinai School of Medicine)

XBiotech

Consultant

Abbvie, Amgen, Bayer, Eli Lilly, Novartis, Janssen, UCB, Celgene, Sanofi-Regeneron, Biogen, Pfizer, and BMS Consulting/Advisory Boards Abbvie, Amgen, BMS, Celgene, Corrona, Gilead, Janssen, Lilly, Novartis, Pfizer, UCB

Grants Pfizer to Penn, Novartis to Penn, Amgen to Forward/NDB

Royalties Novartis to my husband

Other Funding

Dorothy Caputo, MA, BSN, RN - CE Director of Accreditations N/A

LiVDerm Planners and Reviewers N/A NIAMS, Rheumatology Research Foundation, National Psoriasis Foundation, University of Pennsylvania Nothing to disclose

Nothing to disclose

AKH Planners and Reviewers N/A Nothing to disclose

All of the relevant financial relationships listed for these individuals have been mitigated.

Diversity in Derm Treatments: Skin of Color

February 6, 2021

Online

ACTIVITY OVERVIEW

There are gaps in dermatologic care today concerning patients with skin of color (SOC) that need to be addressed through education and putting new knowledge into practice. Patients with SOC can be disproportionately affected by dermatologic conditions such as melasma, acne, rosacea, and hyperpigmentation. Even children with SOC can be more susceptible or have a greater disease burden, especially with conditions such as acne, vitiligo, atopic dermatitis, keloids, pityriasis alba, and traction alopecia. It is important that clinicians are not only aware of these disparities across multiple disease states, but that they are aware of changes to practice that need to be made. The Skin of Color Symposia is designed to address these gaps in dermatologic care for SOC patients by reviewing skin conditions prevalent in SOC patients or those which disproportionately burden SOC patients. Participants will gain education needed to better treat these conditions and modify current practices to accommodate the needs of patients with darker pigmented skin.

TARGET AUDIENCE

This symposium is designed for an audience of physicians, nurses and professional staff members of medical practices specializing in dermatology, plastic surgery, cosmetic surgery and other dermatologic medical procedures.

LEARNING OBJECTIVES

Upon completion of the educational activity, participants should be able to: • Identify the challenges in treating SOC patients for melasma and the considerations that must be made in designing a treatment plan • Review the clinical and aesthetic treatments available for melasma patients • List current and emerging vitiligo treatments for pediatric patients. • Describe the impact of vitiligo in patients with darker pigmented skin and implications for managing vitiligo in this setting. • Classify current and emerging treatments for acne patients, including recommendations for treating the pediatric patient population. • Summarize the challenges associated with different acne and rosacea treatment options for patients with skin of color • Prioritize how to diagnose acne and rosacea in patients with skin of color. • Articulate current and emerging AD treatments for pediatric patients. • Recognize the ways in which pediatric AD patients with SOC are affected in terms of managing their condition. • Distinguish the prevalence of keloids in the SOC population • Recall conventional treatment options for pediatric keloid patients

CRITERIA FOR SUCCESS

Statements of credit will be awarded based on the participant’s attendance and submission of the activity evaluation form. A statement of credit will be available upon completion of an online evaluation/claimed credit form at www.southbeachsymposium.org. You must participate in the entire activity to receive credit. If you have questions about this CE activity, please contact AKH Inc. at tbrignoni@akhcme.com.

Credit provided by AKH Inc., Advancing Knowledge in Healthcare

In support of improving patient care, this activity has been planned and implemented by AKH Inc., Advancing Knowledge in Healthcare and Tarsus Cardio dba LiVDerm. AKH Inc., Advancing Knowledge in Healthcare is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

This activity was planned by and for the healthcare team, and learners will receive 1 Interprofessional Continuing Education (IPCE) credit for learning and change.

Physician

AKH Inc., Advancing Knowledge in Healthcare designates this live activity for a maximum of 1 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurse

1 ANCC contact hours

Physician Assistant

AKH Inc., Advancing Knowledge in Healthcare has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1 AAPA Category 1 CME credits. PAs should only claim credit commensurate with the extent of their participation.

COMMERCIAL SUPPORT

This activity is supported by educational grants from Galderma Laboratories, L.P., Incyte Corporation.

DISCLOSURE

It is the policy of AKH Inc. to ensure independence, balance, objectivity, scientific rigor, and integrity in all of its continuing education activities. The author must disclose to the participants any significant relationships with ineligible companies whose products or devices may be mentioned in the activity or with the commercial supporter of this continuing education activity. Identified conflicts of interest are mitigated by AKH prior to accreditation of the activity. AKH planners and reviewers have no relevant financial relationships to disclose.

DISCLAIMER

This course is designed solely to provide the healthcare professional with information to assist in his/her practice and professional development and is not to be considered a diagnostic tool to replace professional advice or treatment. The course serves as a general guide to the healthcare professional, and therefore, cannot be considered as giving legal, nursing, medical, or other professional advice in specific cases. AKH Inc. specifically disclaim responsibility for any adverse consequences resulting directly or indirectly from information in the course, for undetected error, or through participant’s misunderstanding of the content.

DISCLOSURE OF UNLABELED USE AND INVESTIGATIONAL PRODUCT

This educational activity may include discussion of uses of agents that are investigational and/or unapproved by the FDA. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclosures

NAME RELATIONSHIP COMPANY

Valleri Callender, MD Consultant Janssen , Novartis , UCB

Seemal Desai, MD Speakers Bureau

Advisory Board Aerolase

Dermavan Sciences, Foundation for Research & Education of Dermatology

Consultant Galderma Laboratories, Cassiopea SpA, Ortho Dermatologics, SkinCeuticals LLC, Dermira, Almirall, Scientis Sente Labs, Foamix, Pfizer Inc., Verrica Pharmaceuticals, Inc, Ferndale, Avita, Gore Range Capital, Incyte Corporation, Bristol Myers Squibb, UCB Contracted Research Abbvie, Atacama, Incyte Corporation, Dermavant Sciences, Novan, AOBiome, LLC, Brickell Biotec

Speakers Bureau Almirall, Ortho Dermatologics

Stock Gore Range Capital

Amy McMichael, MD Consultant Allergan, Almirall, Bioniz, Cassiopea, Covance, eResearch Technology, Inc., Galderma, Incyte, Johnson & Johnson, Keranetics, Lilly, Merck & Co., Inc., Pfizer Proctor & Gamble, Revian, Samumed Contracted Research Allergan, Cassiopea, Concert Pharmaceuticals, Incyte, Pfizer Proctor & Gamble, Samumed

Royalties Informa Healthcare, UpToDate

Dorothy Caputo, MA, BSN, RN - CE Director of Accreditations N/A

LiVDerm Planners and Reviewers N/A Nothing to disclose

Nothing to disclose

AKH Planners and Reviewers N/A Nothing to disclose

All of the relevant financial relationships listed for these individuals have been mitigated.

Non Educational Content